Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma Feng-Ling ShaoQing-qing LiuShan Wang CLINICAL TRIAL METHODOLOGY 05 March 2021 Pages: 901 - 913
A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy Nicolas FischerEan-Jeong SeoThomas Efferth PRECLINICAL STUDIES Open access 25 January 2021 Pages: 914 - 927
Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis Bo ChenDonghong SunXing-Hua Gao PRECLINICAL STUDIES 26 January 2021 Pages: 928 - 948
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models Chao ShangYi-Long ZhuNing-Yi Jin PRECLINICAL STUDIES 03 February 2021 Pages: 949 - 960
Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL Linlin ZhaoChengfang LvYinghua Li PRECLINICAL STUDIES 10 February 2021 Pages: 961 - 970
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma Sotiris KyriakouWilliam CheungMihalis I. Panayiotidis PRECLINICAL STUDIES Open access 23 February 2021 Pages: 971 - 986
Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro Oxana O. RyabayaIvan S. AbramovAnastasia A. Prokofieva PRECLINICAL STUDIES 08 March 2021 Pages: 987 - 1000
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors Quincy Siu-chung ChuNathaniel BouganimGerald Batist PHASE I STUDIES 22 January 2021 Pages: 1001 - 1010
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers Yun-ting ZhuYi-fan ZhangDa-fang Zhong PHASE I STUDIES 27 January 2021 Pages: 1011 - 1018
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy Toni K. ChoueiriMichael B. AtkinsDavid F. McDermott PHASE I STUDIES 28 January 2021 Pages: 1019 - 1027
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma Monica BalzarottiMassimo MagagnoliCarmelo Carlo-Stella PHASE I STUDIES Open access 01 February 2021 Pages: 1028 - 1035
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors Noboru YamamotoToshio ShimizuShunji Takahashi PHASE I STUDIES Open access 09 February 2021 Pages: 1036 - 1046
First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies Sarina A. Piha-PaulKyaw Z. TheinBen Markman PHASE I STUDIES 16 February 2021 Pages: 1047 - 1056
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial Afshin DowlatiR. Donald HarveyRobert Wesolowski PHASE I STUDIES 23 February 2021 Pages: 1057 - 1071
Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance) Nguyen H TranNathan R FosterMitesh J. Borad PHASE I STUDIES 01 March 2021 Pages: 1072 - 1080
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma Marjorie G. ZaudererEvan W. AlleyAnna M. Varghese PHASE I STUDIES Open access 04 March 2021 Pages: 1081 - 1088
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors Analia AzaroChristophe MassardShubham Pant PHASE I STUDIES 08 March 2021 Pages: 1089 - 1098
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia Alexey V. DanilovStephen E. SpurgeonJennifer R. Brown PHASE I STUDIES Open access 08 March 2021 Pages: 1099 - 1105
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion Motohiro TamiyaAkihiro TamiyaTomonori Hirashima PHASE II STUDIES 05 February 2021 Pages: 1106 - 1112
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial Anas AlshawaAlexandra Perez CadenaAung Naing PHASE III STUDIES 13 February 2021 Pages: 1113 - 1122
System Xc−: a key regulatory target of ferroptosis in cancer Man-ru LiuWen-tao ZhuDong-sheng Pei Review 27 January 2021 Pages: 1123 - 1131
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors Antian GaoXiao PanZitong Lin REVIEW 16 February 2021 Pages: 1132 - 1138
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis Jorge Antonio Elias Godoy CarlosKeli LimaJoão Agostinho Machado-Neto SHORT REPORT 21 January 2021 Pages: 1139 - 1149
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy Norikazu MatsuoKoichi AzumaTomoaki Hoshino SHORT REPORT 22 January 2021 Pages: 1150 - 1158
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy Francesco PasqualettiAlessandra GonnelliFabiola Paiar SHORT REPORT 08 February 2021 Pages: 1159 - 1165
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy Francesco PasqualettiAlessandra GonnelliFabiola Paiar Correction 11 March 2021 Pages: 1166 - 1166
Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings Masahiro WadaAkihiko OzakiAndy Crump SHORT REPORT 09 February 2021 Pages: 1167 - 1169
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy Yuki SatoTakeshi MorimotoKeisuke Tomii SHORT REPORT 10 February 2021 Pages: 1170 - 1178
Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition Yuqiang HuMing HaoLiangjun Cheng SHORT REPORT 01 March 2021 Pages: 1179 - 1188
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients Julian TaugnerLukas KäsmannFarkhad Manapov SHORT REPORT Open access 11 March 2021 Pages: 1189 - 1196
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA Shouhua PanSi LiJunlong Li SHORT REPORT 20 March 2021 Pages: 1197 - 1199